{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-017422","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-10-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.181555+00:00","generated_at":"2026-05-17T04:21:40.364276+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Telomir-1 selectively kills triple-negative breast cancer cells in lab studies","bullets":["Telomir-1 produced concentration-dependent reduction in TNBC cell survival; iron addition reversed effect, confirming iron-dependent mechanism.","Compound targets aggressive TNBC cells' metabolic reliance on iron, potentially sparing healthy tissue due to differing iron management.","Findings link Telomir-1's effect to Jumonji domain histone demethylases (KDM5A/B, KDM6B) involved in cancer aggression and therapy resistance.","Company plans to expand studies to pancreatic and leukemia models, and conduct animal studies ahead of IND submission."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-017422","json":"https://secwatch.observer/filing/0001493152-25-017422.json","markdown":"https://secwatch.observer/filing/0001493152-25-017422.md","text":"https://secwatch.observer/filing/0001493152-25-017422.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225017422/0001493152-25-017422-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225017422/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:21:40.364276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}